Securities code: 002317 Announcement No.: 2022-002
Guangdong Zhongsheng Pharmaceutical Co.Ltd(002317)
Announcement on abnormal fluctuations in the company’s stock trading
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Introduction to abnormal fluctuations in stock trading
Guangdong Zhongsheng Pharmaceutical Co.Ltd(002317) (hereinafter referred to as “the company”) shares (Securities abbreviation: Guangdong Zhongsheng Pharmaceutical Co.Ltd(002317) , securities code: 002317) have deviated from the daily closing price by more than 20% in two consecutive trading days on January 10 and January 11, 2022. According to the trading rules of Shenzhen Stock Exchange and other relevant regulations, they belong to abnormal fluctuations in stock trading.
2、 The company pays attention to and verifies relevant information
In view of the abnormal fluctuation of the company’s shares, the company has checked the relevant matters, and the relevant information is described as follows:
1. The company does not find any information disclosed in the previous period that needs to be corrected or supplemented;
2. The company has not found any unpublished material information that may or has had a great impact on the stock trading price of the company reported by the public media recently;
3. At present, the company’s operation is normal, and the internal and external business environment has not changed significantly;
4. The company, the controlling shareholder and the actual controller do not have any major events that should be disclosed but not disclosed about the company, nor do they have any major events in the planning stage;
5. The controlling shareholder and actual controller of the company did not buy or sell the company’s shares during the abnormal fluctuation of the company’s stock trading.
3、 Whether there is a description of information that should be disclosed but not disclosed
The board of directors of the company confirms that the company has no undisclosed matters or planning, negotiation, intention and agreement related to the matters that should be disclosed in accordance with the stock listing rules of Shenzhen Stock Exchange and other relevant provisions
Securities code: 002317 Announcement No.: 2022-002
Discussion, etc; The board of directors has not been informed that the company has undisclosed information that should be disclosed in accordance with the stock listing rules of Shenzhen Stock Exchange and other relevant provisions and has a great impact on the trading price of the company’s shares and their derivatives; There is no need to correct or supplement the information disclosed by the company in the early stage.
4、 Risk tips
1. After self-examination, the company does not violate the fair disclosure of information.
2. The company disclosed the performance forecast for 2021 on January 6, 2022. It is estimated that the net profit attributable to the shareholders of the listed company in 2021 will be 330 million yuan to 390 million yuan, turning losses into profits compared with the same period of the previous year. As of the disclosure date of this announcement, the above performance is not expected to be corrected. The specific financial data of the company in 2021 shall be subject to the annual report of the company in 2021.
3. Securities times and cninfo (www.cn. Info. Com. CN.) For the information disclosure media selected by the company, all information of the company shall be subject to the information disclosed in the above media.
The company will conscientiously perform the obligation of information disclosure and do a good job of information disclosure in a timely manner in strict accordance with the provisions and requirements of relevant laws and regulations. Please invest rationally and pay attention to risks.
It is hereby announced.
Guangdong Zhongsheng Pharmaceutical Co.Ltd(002317) board of directors January 11, 2002
